Reglagene, a Tucson-based developer of quadruplex master switch technology that enables the discovery of medicines that control gene expression, placed second in the RESI Innovation Challenge during JPM Week in San Francisco. Hosted by Life Science Nation (LSN), RESI conferences bring together global early-stage companies across Biotech, Medtech, Diagnostics & Digital Health with life science strategics, family offices, venture funds and angel investors.
The RESI Challenge features 30 early stage life science companies from around the world that are selected by Life Science Nation’s internal scientific review board to be part of the RESI Innovation Challenge, presenting their technologies in an exhibition-style format throughout the full-day conference.
Attendees at the RESI conference are provided with RESI Bucks to “invest” in the most promising companies during the full day event. The capital invested is then tallied up and the top three winners receive prizes and are featured in the RESI newsletter recap that goes out to LSN’s 23,000 newsletter readership. to meet with some of the top innovators in the field and invest your “RESI Cash.”
This is the second “big win” for Reglagene in the last 60 days. The company was announced as a winner of the Fall 2019 Arizona Innovation Challenge on December 11, 2019. A business plan competition for promising early stage companies in high-growth industries awards $1.5 million twice a year. The winners will receive as much as $150,000 each, released in phases as each company reaches certain milestones as well as the benefit of participating in the Arizona Commerce Authority’s Venture Ready Accelerator, which connects companies with serial entrepreneurs, high-level executives and subject matter experts. The program is designed to help startups refine their business plan, improve go-to-market strategies and increase investor readiness.